Melanoma In Dogs: Comprehensive Veterinary Reference Guide

Melanoma is one of the most clinically significant neoplasms encountered in canine practice. While many cutaneous melanocytic tumours in dogs are benign, malignant melanoma (particularly of the oral cavity, nail bed, and mucocutaneous junctions) carries a guarded to poor prognosis due to its high metastatic potential and locally aggressive behaviour. This comprehensive veterinary reference guide provides an exhaustive, evidence-informed overview of melanoma in dogs, covering aetiology, clinical presentation, diagnostic workup, staging, therapeutic options (including surgery, radiation therapy, immunotherapy, and chemotherapy), and long-term management. This article is intended for veterinary professionals, veterinary students, and dedicated pet owners seeking a deep understanding of this challenging disease.

Quick Q&A: Canine Melanoma

Question: What is the most common and aggressive form of melanoma in dogs, and what is the typical survival time?

Answer: The most common and aggressive form is oral malignant melanoma. Without treatment, survival is often measured in weeks to a few months. With aggressive local therapy (surgery and/or radiation) combined with immunotherapy (the canine melanoma vaccine), median survival times can extend to 12-18 months or longer, depending on stage and completeness of excision.

1. Introduction and Epidemiology

Melanocytes are melanin-producing cells derived from the neural crest. They reside in the basal layer of the epidermis, the oral epithelium, the uveal tract of the eye, and other sites. Neoplasia arising from these cells is termed melanoma. In dogs, melanocytic tumours are extremely common, accounting for approximately 3-7% of all canine neoplasms. However, the biological behaviour of these tumours varies dramatically by anatomic location.

Cutaneous (skin) melanomas in dogs are predominantly benign (approximately 70-85%), whereas oral, subungual (nail bed), and mucocutaneous melanomas are overwhelmingly malignant. Oral malignant melanoma (OMM) is the most common oral malignancy in dogs, representing 30-50% of all oral tumours. It is highly invasive locally and metastasises early, most frequently to regional lymph nodes and the lungs. According to the Merck Veterinary Manual, canine oral melanoma is one of the most aggressive neoplasms in veterinary medicine.

Breed predispositions are well documented. Breeds with heavily pigmented oral mucosa, such as Chow Chows, Scottish Terriers, Golden Retrievers, and Labrador Retrievers, appear overrepresented. However, any breed can be affected. The median age at presentation is 10-12 years, with no strong sex predilection, though some studies report a slight male predominance.

2. Aetiology and Risk Factors

The precise aetiology of canine melanoma is not fully understood. Unlike in humans, where ultraviolet (UV) radiation is a major risk factor for cutaneous melanoma, UV exposure does not appear to play a significant role in canine melanoma. This is supported by the fact that canine melanomas often arise in non-sun-exposed areas (e.g., oral cavity, nail bed) and that pigmented breeds are at higher risk.

Genetic factors are increasingly recognised. Mutations in the BRAF gene, common in human melanoma, are rare in canine melanoma. Instead, alterations in the RAS/RAF/MEK/ERK pathway, as well as mutations in TP53, PTEN, and KIT, have been identified in a subset of canine melanomas. The canine melanoma vaccine (Oncept) targets the enzyme tyrosinase, which is overexpressed in canine melanoma cells.

Breed and pigmentation: Dogs with heavily pigmented skin and oral mucosa are at higher risk. This suggests a potential role for melanin or melanocyte biology in tumourigenesis, though the mechanism remains unclear.

Chronic inflammation or trauma: Some hypothesise that chronic irritation (e.g., from dental disease or trauma to the nail bed) may contribute, but definitive evidence is lacking.

3. Clinical Classification and Anatomic Subtypes

Melanoma in dogs is classified by anatomic site, as this is the single most important prognostic factor.

3.1 Oral Malignant Melanoma (OMM)

OMM is the most common oral malignancy in dogs. It typically presents as a pigmented (black, brown, or grey) or non-pigmented (amelanotic) mass on the gingiva, hard palate, tongue, or lips. Amelanotic melanomas are particularly challenging as they can be misdiagnosed as other soft tissue sarcomas or carcinomas.

Clinical features:

• Rapidly growing, often ulcerated mass
• Halitosis, ptyalism (drooling), dysphagia, oral bleeding
• Mobile or loose teeth (due to bone invasion)
• Pain on opening the mouth or eating
• Regional lymphadenopathy (mandibular or retropharyngeal nodes)

OMM is highly invasive into underlying bone (mandibulectomy or maxillectomy specimens often show medullary invasion). Metastasis to regional lymph nodes occurs early; up to 50-80% of dogs have lymph node metastasis at the time of diagnosis. Distant metastasis (lungs, liver, spleen, brain) is common later in the disease.

3.2 Cutaneous Melanoma

Cutaneous melanomas arise from melanocytes in the skin. The vast majority (70-85%) are benign in dogs, though malignant cutaneous melanomas do occur, particularly on the trunk and extremities.

Benign cutaneous melanoma (melanocytoma): Typically small (<2 cm), dome-shaped, well-circumscribed, slow-growing, and often pigmented. They are considered benign and surgical excision is curative.

Malignant cutaneous melanoma: Larger, irregular, rapidly growing, ulcerated, and may be non-pigmented. These are more aggressive, with metastatic potential. However, even malignant cutaneous melanomas carry a better prognosis than oral or subungual forms.

3.3 Subungual (Nail Bed) Melanoma

Subungual melanoma arises from melanocytes within the nail bed. It is almost always malignant. It typically presents as a swollen, painful digit with nail loss, paronychia, or a visible mass at the nail base. It is often misdiagnosed as a bacterial or fungal infection (onychitis) or a foreign body.

Key points:

• Most common in large breed, dark-pigmented dogs (e.g., Labrador Retrievers, Standard Poodles)
• Typically affects a single digit, but multiple digits can be involved
• Early metastasis to regional lymph nodes (axillary or inguinal) and lungs
• Treatment is digit amputation (phalangectomy) with lymph node evaluation

3.4 Ocular Melanoma

Ocular melanomas can arise from the uveal tract (iris, ciliary body, choroid) or the conjunctiva. Uveal melanoma is the most common primary intraocular tumour in dogs.

Clinical signs: Visible pigmented mass in the iris or anterior chamber, glaucoma, uveitis, buphthalmos (eye enlargement), or blindness.

Behaviour: Uveal melanomas in dogs are generally considered benign, with low metastatic potential. However, they can cause significant ocular morbidity (glaucoma, pain). Conjunctival melanomas are rarer and may be more aggressive. Enucleation is the standard treatment for uveal melanoma causing secondary glaucoma or pain.

3.5 Other Sites

Melanomas can also occur in the central nervous system (meninges), the gastrointestinal tract, and the genital mucosa, though these are rare.

4. Histopathology and Grading

Definitive diagnosis requires histopathological examination of a biopsy specimen (incisional or excisional). Key histologic features include:

• Cell morphology: Epithelioid, spindle, or mixed cell populations. Cells contain variable amounts of melanin pigment. Amelanotic melanomas require immunohistochemistry for diagnosis.
• Junctional activity: Presence of neoplastic melanocytes at the dermo-epidermal junction is characteristic of melanoma.
• Mitotic index (MI): This is the most important histologic prognostic factor. A high MI (>4 mitoses per 10 high-power fields) is associated with malignant behaviour.
• Nuclear atypia: Pleomorphism, prominent nucleoli.
• Lymphovascular invasion: Strongly associated with metastasis.
• Bone invasion: Common in oral and subungual forms.

Immunohistochemistry (IHC): Melan A, PNL2, and tyrosinase are sensitive and specific markers for canine melanoma. S100 is also used but is less specific. IHC is essential for diagnosing amelanotic melanomas and for confirming the diagnosis in challenging cases.

Grading systems: Several grading schemes exist, but none are universally adopted. The most clinically useful system is based on mitotic index and nuclear atypia, classifying tumours as low, intermediate, or high grade. High-grade tumours have a high MI, severe atypia, and a high likelihood of metastasis.

5. Diagnostic Workup and Staging

A thorough diagnostic workup is essential for accurate staging, prognostication, and treatment planning. The goal is to confirm the diagnosis, assess local tumour extent, and identify regional or distant metastasis.

5.1 Physical Examination and Oral Examination

Complete physical examination, including careful palpation of regional lymph nodes (mandibular, retropharyngeal, prescapular, axillary, inguinal, and popliteal). For oral masses, a thorough oral examination under sedation or anaesthesia is required. Document the size, location, colour, and consistency of the mass. Assess for bone involvement (hard palate, mandible).

5.2 Cytology

Fine needle aspiration (FNA) of the primary mass and any enlarged lymph nodes can be performed. Cytology of pigmented melanomas often reveals melanin-laden cells, but accuracy is limited (false negatives are common, especially for amelanotic forms). FNA of lymph nodes is essential for staging; however, a negative FNA does not rule out micrometastasis. Lymph node extirpation and histopathology are more sensitive.

5.3 Biopsy and Histopathology

An incisional biopsy (wedge or punch) or excisional biopsy (if the mass is small and accessible) should be performed. The sample should include the deep margin and adjacent normal tissue. For oral masses, a deep wedge biopsy is preferred. Submit the sample for histopathology and IHC if needed.

5.4 Imaging

Thoracic radiographs (three views): Essential for detecting pulmonary metastasis. However, radiographs are insensitive for small nodules (<1 cm). CT is superior.

Computed tomography (CT): The gold standard for staging canine melanoma. CT of the head and neck (for oral tumours) allows assessment of bone invasion, extent of the mass, and regional lymph node involvement. CT of the thorax is more sensitive than radiographs for detecting pulmonary metastasis. CT is also used for radiation therapy planning.

Abdominal ultrasound: Recommended for advanced cases to evaluate for abdominal metastasis (liver, spleen, lymph nodes).

5.5 Lymph Node Staging

Regional lymph node status is the single most important prognostic factor. Techniques include:

• FNA cytology: Quick but less sensitive.
• Surgical extirpation (lymphadenectomy): Provides definitive histologic diagnosis. Mandibular and retropharyngeal nodes are most commonly sampled for oral tumours.
• Sentinel lymph node mapping: Increasingly used in veterinary oncology. Injection of a dye or radiocolloid around the tumour helps identify the first draining lymph node, which is then excised and examined. This technique improves detection of occult metastasis.

5.6 Staging System

The World Health Organisation (WHO) TNM (Tumour, Node, Metastasis) staging system is used for canine oral melanoma:

• T (Primary tumour):
  • T1: <2 cm diameter
  • T2: 2-4 cm diameter
  • T3: >4 cm diameter
  • T4: Bone invasion
• N (Regional lymph node):
  • N0: No metastasis
  • N1: Ipsilateral node metastasis
  • N2: Contralateral or bilateral node metastasis
• M (Distant metastasis):
  • M0: No distant metastasis
  • M1: Distant metastasis present

Stage grouping:

• Stage I: T1 N0 M0
• Stage II: T2 N0 M0
• Stage III: T3 N0 M0 or any T N1 M0
• Stage IV: any T any N M1

Median survival times decrease dramatically with increasing stage. Stage I tumours with complete excision can have median survival >2 years, whereas Stage IV disease has a median survival of <3 months without treatment.

6. Treatment Modalities

Treatment of canine melanoma is multimodal. The approach depends on the anatomic site, stage, tumour grade, and the dog's overall health.

6.1 Surgery

Surgery is the cornerstone of treatment for localised melanoma. The goal is complete excision (histologically clean margins). For oral melanoma, this often requires aggressive surgery such as:

• Mandibulectomy (partial, segmental, or bilateral) for mandibular tumours.
• Maxillectomy (partial or total) for maxillary or hard palate tumours.
• Glossectomy for lingual tumours.

Surgery for subungual melanoma involves digit amputation (phalangectomy) at the level of the metacarpophalangeal or metatarsophalangeal joint. For cutaneous melanomas, wide local excision (1-2 cm margins) is recommended.

Prognostic impact of surgical margins: Clean margins are associated with significantly longer survival. However, even with clean margins, the risk of metastasis remains high, especially for oral and subungual forms. Therefore, surgery is often combined with adjuvant therapy.

6.2 Radiation Therapy

Radiation therapy (RT) is highly effective for local control of canine melanoma. Melanoma is considered moderately radiosensitive, but the response is often dose-dependent. RT is used in several settings:

• Definitive RT: For non-resectable tumours or when surgery is declined. Coarse fractionation protocols (e.g., 4 x 8 Gy fractions) are commonly used. Response rates are high (70-90%), with durable local control.
• Adjuvant RT: After incomplete surgical excision to reduce local recurrence.
• Palliative RT: To relieve pain, bleeding, or obstruction in advanced cases.

Side effects include acute mucositis (for oral RT), dermatitis, and alopecia. These are typically self-limiting.

6.3 Immunotherapy (Melanoma Vaccine)

The canine melanoma vaccine (Oncept, Merial) is a xenogeneic DNA vaccine encoding human tyrosinase. It stimulates the dog's immune system to target tyrosinase-expressing melanoma cells. It is approved for the treatment of Stage II and III oral melanoma (after local control) and is used off-label for other stages and sites.

Protocol: A series of 4 intradermal vaccinations (every 2 weeks) followed by boosters every 6 months. The vaccine is well tolerated, with minimal side effects (local injection site reaction, mild lethargy).

Efficacy: Clinical trials have shown that dogs receiving the vaccine after local control (surgery and/or RT) have significantly longer median survival times (12-18 months) compared to historical controls (4-6 months). The vaccine is most effective in dogs with minimal disease burden.

Important note: The vaccine is not a standalone treatment. It is an adjuvant therapy used after achieving local control.

6.4 Chemotherapy

Chemotherapy has limited efficacy against canine melanoma. The disease is considered chemoresistant. However, chemotherapy may be used in certain situations:

• Palliative therapy: For metastatic disease. Drugs used include carboplatin, cisplatin, dacarbazine (DTIC), and temozolomide. Response rates are low (10-20%) and of short duration.
• Adjuvant therapy: There is no strong evidence that adjuvant chemotherapy improves survival after local control. It is not routinely recommended.
• Intralesional chemotherapy: Bleomycin or cisplatin injected directly into the tumour may provide local control in some cases.

6.5 Targeted Therapy and Emerging Treatments

Recent advances in molecular oncology have identified potential therapeutic targets:

• KIT inhibitors: Mutations in KIT are found in a subset of canine melanomas. Tyrosine kinase inhibitors (TKIs) such as toceranib (Palladia) or masitinib (Masivet) may be effective in KIT-positive tumours. Response rates are variable.
• MEK inhibitors: Trametinib and other MEK inhibitors are being investigated. They target the MAPK pathway, which is activated in many canine melanomas.
• Checkpoint inhibitors: Anti-PD-1 and anti-PD-L1 antibodies (e.g., pembrolizumab, nivolumab) have revolutionised human melanoma treatment. Canine-specific checkpoint inhibitors are under development and have shown promise in early studies. They may become available in the future.
• Electrochemotherapy: Combines chemotherapy (bleomycin) with electrical pulses to enhance drug uptake. It is used for local control of cutaneous and oral tumours.

6.6 Palliative Care

For advanced or metastatic disease, the focus shifts to quality of life. Palliative options include:

• Pain management (NSAIDs, opioids, gabapentin, amantadine)
• Nutritional support (soft food, feeding tubes)
• Antibiotics for secondary infections
• Palliative RT for pain relief
• Corticosteroids for appetite stimulation and anti-inflammatory effects

7. Prognosis and Survival

Prognosis depends on several factors:

Median survival times (approximate):

• Stage I oral melanoma (complete excision): 24-36 months
• Stage II oral melanoma (complete excision + vaccine): 12-18 months
• Stage III oral melanoma (lymph node positive): 6-12 months
• Stage IV oral melanoma (distant metastasis): 1-3 months
• Subungual melanoma (digit amputation + vaccine): 12-18 months
• Malignant cutaneous melanoma (wide excision): 12-24 months

8. Regional Considerations and Guidelines

8.1 United States and Canada

The American Veterinary Medical Association (AVMA) and the American Animal Hospital Association (AAHA) provide guidelines for cancer care in dogs. The AAHA Oncology Guidelines for Dogs and Cats (2016) recommend a multidisciplinary approach for melanoma, including staging with advanced imaging (CT) and sentinel lymph node mapping. The canine melanoma vaccine (Oncept) is approved by the USDA and is widely used in the US and Canada.

In Canada, the Canadian Veterinary Medical Association (CVMA) endorses the same principles. Access to advanced therapies (RT, immunotherapy) may be limited to specialty referral centres.

8.2 Europe

The Federation of Veterinarians of Europe (FVE) and the European Medicines Agency (EMA) oversee veterinary medicines. Oncept is approved in the European Union under a conditional marketing authorisation. Availability varies by country. Radiation therapy is available at many university hospitals and private referral centres. The European Society of Veterinary Oncology (ESVONC) provides guidelines for melanoma management.

8.3 Australia

The Australian Veterinary Association (AVA) and the Department of Agriculture, Fisheries and Forestry (DAFF) regulate veterinary medicines. Oncept is registered in Australia and is available through veterinary oncologists. Australia has strict quarantine laws, but these do not affect the availability of melanoma treatments. Canine melanoma is less studied in Australian dogs, but the same principles apply. Tick-borne diseases (e.g., Ehrlichiosis, Babesiosis) are a consideration in some regions, but they do not directly affect melanoma management.

9. Prevention and Surveillance

There is no proven method to prevent canine melanoma. However, early detection improves outcomes. Recommendations include:

• Regular oral examinations: At least annually, more frequently for high-risk breeds (Chow Chows, Scottish Terriers, Golden Retrievers).
• Dental cleanings: Provide an opportunity for thorough oral inspection.
• Nail bed monitoring: Check for swelling, discharge, or nail loss. Any persistent digit lesion should be biopsied.
• Skin checks: Monitor pigmented masses for changes in size, shape, or colour. Any rapidly growing or ulcerated skin mass should be evaluated.
• Genetic testing: Not currently available for canine melanoma risk.

Post-treatment surveillance:

• Physical examination every 2-3 months for the first year, then every 3-6 months thereafter.
• Thoracic radiographs or CT every 3-6 months.
• Lymph node palpation and FNA if enlarged.
• Oral examination (for oral melanoma) every 3 months.

10. Frequently Asked Questions (FAQs)

Q: Can melanoma in dogs be cured? A: Complete cure is possible for early-stage cutaneous melanomas (benign) and some oral melanomas if completely excised with clean margins and no metastasis. However, for most malignant melanomas, the goal is long-term control rather than cure. Multimodal therapy can achieve survival times of 1-2 years or more.

Q: Is the melanoma vaccine painful for dogs? A: The vaccine is given as an intradermal injection, similar to a standard vaccination. Some dogs may experience mild discomfort at the injection site. Serious side effects are rare.

Q: How much does melanoma treatment cost? A: Costs vary widely. Surgery (mandibulectomy or maxillectomy) can cost $2,000-$6,000. Radiation therapy ranges from $3,000-$8,000. The melanoma vaccine costs approximately $200-$300 per dose (4 doses initially, then boosters). Chemotherapy adds additional costs. Pet insurance can help offset expenses.

Q: Are there any home remedies for melanoma in dogs? A: No. Melanoma is a serious, life-threatening disease. There are no proven home remedies. Any treatment should be under the direction of a veterinary oncologist. Delaying conventional treatment can worsen the prognosis.

Q: What is the difference between a melanocytoma and a malignant melanoma? A: A melanocytoma is a benign melanocytic tumour. It is small, slow-growing, and does not metastasise. A malignant melanoma is invasive, grows rapidly, and can spread to lymph nodes and distant organs. Histopathology is required to differentiate them.

11. Conclusion

Melanoma in dogs is a complex and aggressive neoplasm, particularly when it arises in the oral cavity, nail bed, or mucocutaneous junctions. Early diagnosis, accurate staging (including lymph node evaluation and advanced imaging), and aggressive multimodal therapy are essential for optimising outcomes. Surgery remains the mainstay of local control, while radiation therapy and the canine melanoma vaccine have significantly improved survival times. Chemotherapy and targeted therapies play a limited but evolving role.

Veterinary professionals should maintain a high index of suspicion for any pigmented or non-pigmented mass in high-risk sites. Pet owners should be educated about the importance of regular oral and skin examinations. With advances in immunotherapy and molecular targeted therapy, the future holds promise for even better outcomes for dogs diagnosed with this challenging disease.

References

1. Bergman, P. J. (2007). Canine oral melanoma. Clinical Techniques in Small Animal Practice, 22(2), 55-60.
2. Smith, S. H., Goldschmidt, M. H., & McManus, P. M. (2002). A comparative review of melanocytic neoplasms. Veterinary Pathology, 39(6), 651-678.
3. Bostock, D. E. (1979). Prognosis after surgical excision of canine melanomas. Veterinary Pathology, 16(1), 32-40.
4. Smedley, R. C., Spangler, W. L., Esplin, D. G., et al. (2011). Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation. Veterinary Pathology, 48(1), 54-72.
5. Proulx, D. R., Ruslander, D. M., & Dodge, R. K. (2003). A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation therapy. Veterinary Radiology & Ultrasound, 44(3), 352-359.
6. Bergman, P. J., McKnight, J., Novosad, A., et al. (2006). Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clinical Cancer Research, 12(7 Pt 1), 2165-2170.
7. Grosenbaugh, D. A., Leard, A. T., Bergman, P. J., et al. (2011). Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision. Veterinary Immunology and Immunopathology, 142(3-4), 177-184.
8. Boston, S. E., Lu, X., Culp, W. T., et al. (2014). Efficacy of toceranib phosphate (Palladia) in dogs with malignant melanoma. Journal of Veterinary Internal Medicine, 28(5), 1476-1482.
9. Wobeser, B. K., Kidney, B. A., Powers, B. E., et al. (2007). Agreement between histopathologic diagnosis and immunohistochemical detection of melanocytic markers in canine oral melanomas. Veterinary Pathology, 44(6), 828-834.
10. American Animal Hospital Association (AAHA). (2016). AAHA Oncology Guidelines for Dogs and Cats. Journal of the American Animal Hospital Association, 52(4), 181-204.
11. Merck Veterinary Manual. (2023). Neoplasms of the Oral Cavity in Dogs. Retrieved from www.merckvetmanual.com.
12. European Society of Veterinary Oncology (ESVONC). (2020). Guidelines for the Management of Canine Oral Melanoma.
13. Vail, D. M., & Thamm, D. H. (2020). Withrow and MacEwen's Small Animal Clinical Oncology (6th ed.). Elsevier.
14. Ehrhart, N. P., & Withrow, S. J. (2007). Tumors of the Skeletal System. In Small Animal Clinical Oncology (4th ed.), pp. 540-562. Saunders.
15. Liptak, J. M., & Withrow, S. J. (2007). Cancer of the Gastrointestinal Tract. In Small Animal Clinical Oncology (4th ed.), pp. 455-510. Saunders.